RecruitingPhase 2NCT07525427
Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis
Studying Primary pulmonary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gates Medical Research Institute
- Principal Investigator
- Gates MRIGates Medical Research Institute
- Intervention
- Bedaquiline, pretomanid and TBD09(drug)
- Enrollment
- 150 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2026 – 2026
Study locations (13)
- Enhancing Care Foundation at Wentworth Hospital, Durban, Bluff, South Africa
- TASK Applied Science - Eden, George, Central, South Africa
- Clinical Research and HIV Research Unit (CHRU) @ Helen Joseph Hospital, Johannesburg, Gauteng, South Africa
- The Aurum Institute Tembisa, Tembisa, Gauteng, South Africa
- CHRU @ Isango Lethemba, Bethelsdorp, Gqeberha, South Africa
- Madibeng Centre for Research, Brits, North West, South Africa
- Setshaba Research Center, Pretoria, Soshangue, South Africa
- ONE MRI, Cape Town, Western Cape, South Africa
- TASK Applied Science - Brookylyn Chest Hospital, Cape Town, Western Cape, South Africa
- BioMedical Research Institute - Stellenbosch University @ Tygerberg Hospital, Cape Town, Western Cape, South Africa
- UCT Lung Institute, Cape Town, Western Cape, South Africa
- Desmond Tutu Health Foundation, Cape Town, Western Cape, South Africa
- Synergy Biomedical Research Institute (SBRI), East London, South Africa
Collaborators
IQVIA RDS Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07525427 on ClinicalTrials.govOther trials for Primary pulmonary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07517445Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary TuberculosisGates Medical Research Institute
- RECRUITINGNANCT07484490Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in TuberculosisRiphah International University
- RECRUITINGPHASE3NCT07209761A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary TuberculosisOtsuka Pharmaceutical Development & Commercialization, Inc.
- RECRUITINGPHASE2NCT07170800A Phase 2b Clinical Study of JDB0131 Benzenesulfonate TabletsWestVac Biopharma Co., Ltd.
- RECRUITINGPHASE2NCT06192160Trial of Novel Regimens for the Treatment of Pulmonary TuberculosisNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE2NCT06748937A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With EthionamideTASK Applied Science
- ACTIVE NOT RECRUITINGNANCT07186478I-FALMIN Albumin Supplement for Patients With Pulmonary TuberculosisHasanuddin University
- ACTIVE NOT RECRUITINGPHASE3NCT06649721Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese CohortHuashan Hospital